A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)
2018년 9월 24일 업데이트: Merck Sharp & Dohme LLC
A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)
The purpose of this randomized, double-blind, placebo-controlled, 5-period crossover study is to assess the effect of single oral doses of MK-1064 on latency to persistent sleep (LPS) as measured by polysomnography (PSG) in healthy young male participants, and to evaluate the safety and tolerability of single oral doses of MK-1064 and MK-6096 in healthy young male participants.
The primary efficacy hypothesis is that at least one dose of MK-1064 is superior to placebo in decreasing LPS in healthy male participants as assessed by PSG.
연구 개요
연구 유형
중재적
등록 (실제)
20
단계
- 1단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
남성
설명
Inclusion Criteria:
- Body Mass Index (BMI) ≤31 kg/m^2
- In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
- Nonsmoker and has not used nicotine or nicotine-containing products for at least 6 months
- No history of any sleep disorder
- Has not used prescription or over the counter sedation or alerting medication in 4 weeks prior to screening
- Participant has a usual bedtime between 8:00 PM and 12:00 AM
- Participant has total sleep duration of ≥6.5 and ≤9 hours during the 4 weeks prior to screening
- Male participants with female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study and for 90 days after the last dose of study drug
Exclusion Criteria:
- Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder within the last 10 years
- History of any persistent sleep abnormality (including difficulty falling asleep, difficulty staying asleep) lasting for 3 months or more, or history of obstructive sleep apnea, restless leg syndrome, or narcolepsy
- History of clinically significant sleep disorders within the last 5 years
- History of circadian rhythm sleep disorder, clinically important parasomnia, or primary insomnia
- History of repeated falls or fractures secondary to falling within the past 2 years
- Participant works a night shift and is not able to avoid night shift work a minimum of 1 week prior to screening and for the duration of the study
- Participant has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study
- Is a regular user of sedative-hypnotic agents
- History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- History of stroke, peripheral neuropathy, chronic seizures or other clinically significant neurological disorder or cognitive impairment
- History of cancer
- History of cataplexy
- Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study
- Participant consumes >3 servings of alcohol a day
- Participant consumes >6 caffeine servings a day
- Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening, or participated in another investigational study within 3 months prior to first dose of study drug
- History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
- Is currently a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within 2 years of screening
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
실험적: Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
실험적: Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
|
실험적: Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo
For overall study population, 5 participants each were to be allocated to one of 4 sequences.
In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo.
Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation.
There was a minimum 7-day washout between doses.
|
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Latency to Persistent Sleep (LPS) Following Single Doses of MK-1064 and Placebo
기간: 1 to 9 hours post dose, within each treatment period
|
LPS is measured during overnight sleep laboratory (polysomnography [PSG]) assessment and is defined as the duration of time from the beginning of PSG assessment to the first interval of 10 consecutive minutes of sleep.
|
1 to 9 hours post dose, within each treatment period
|
|
LPS Following Single Doses of MK-6096 and Placebo
기간: 1 to 9 hours post dose, within each treatment period
|
LPS is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of time from the beginning of PSG assessment to the first interval of 10 consecutive minutes of sleep.
|
1 to 9 hours post dose, within each treatment period
|
|
Number of Participants With Adverse Events (AEs)
기간: Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE.
|
Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
|
Number of Participants Who Discontinued Study Due to an AE
기간: Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE.
|
Up to 14 days after the last dose of study drug (Up to approximately 42 days)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Wake Time After Sleep Onset (WASO) Following Single Doses of MK-1064 and Placebo
기간: 1 to 9 hours post dose, within each treatment period
|
WASO is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning.
|
1 to 9 hours post dose, within each treatment period
|
|
WASO Following Single Doses of MK-6096 and Placebo
기간: 1 to 9 hours post dose, within each treatment period
|
WASO is measured during overnight sleep laboratory (PSG) assessment and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning.
|
1 to 9 hours post dose, within each treatment period
|
|
Change From Baseline in Choice Reaction Time (CRT) Following Single Doses of MK-1064 and Placebo
기간: Pre-dose and 10 hours post dose, within each treatment period
|
CRT assessment used in this study is a two-choice, computer-controlled test in which the participant responds to stimulus words presented on the screen of a laptop computer.
During the test either the word "NO" or the word "YES" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 50 trials for which each stimulus word is chosen randomly with equal probability and there is a varying inter-stimulus interval.
The mean reaction time of accurate responses is determined.
The assessment is performed pre-dose and at 10 hours post dose.
The outcome measure is change from baseline to post dose in reaction time.
|
Pre-dose and 10 hours post dose, within each treatment period
|
|
Change From Baseline in CRT Following Single Doses of MK-6096 and Placebo
기간: Pre-dose and 10 hours post dose, within each treatment period
|
CRT assessment used in this study is a two-choice, computer-controlled test in which the participant responds to stimulus words presented on the screen of a laptop computer.
During the test either the word "NO" or the word "YES" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 50 trials for which each stimulus word is chosen randomly with equal probability and there is a varying inter-stimulus interval.
The mean reaction time of accurate responses is determined.
The assessment is performed pre-dose and at 10 hours post dose.
The outcome measure is change from baseline to post dose in reaction time.
|
Pre-dose and 10 hours post dose, within each treatment period
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2009년 11월 6일
기본 완료 (실제)
2010년 4월 6일
연구 완료 (실제)
2010년 4월 6일
연구 등록 날짜
최초 제출
2015년 9월 11일
QC 기준을 충족하는 최초 제출
2015년 9월 11일
처음 게시됨 (추정)
2015년 9월 14일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2018년 10월 23일
QC 기준을 충족하는 마지막 업데이트 제출
2018년 9월 24일
마지막으로 확인됨
2018년 9월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 1064-003
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
예
IPD 계획 설명
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
연구 데이터/문서
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .